The role of biomarkers in the management of patients with lymphoma: Promise versus reality

Clinical Lymphoma and Myeloma

Volumn 9, Issue 2, 2009, Pages 121-123

  Hsi, Eric ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 8; LEUKOSIALIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PREDNISONE; RITUXIMAB; VINCRISTINE; TUMOR MARKER;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL MIGRATION; CELL SURVIVAL; CHROMOSOME 1P; CHROMOSOME 6P; DISEASE FREE SURVIVAL; DISOMY; DNA REPAIR; GENE EXPRESSION PROFILING; GRANULOCYTIC SARCOMA; HUMAN; LYMPHOMA; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LYMPHOMA; EDITORIAL; GENETICS; METABOLISM; PROGNOSIS;

HUMANS; LYMPHOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650657869     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.031     Document Type: Editorial

References (42)

1. Mitrovic V, Ilic I, Nola M, et al. CD43 expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma 2009; 9:133-7.
2. Matsumoto M, Shigeta A, Furukawa Y, et al. CD43 collaborates with P-selectin glycoprotein ligand-1 to mediate E-selectin-dependent T cell migration into inflamed skin. J Immunol 2007; 178:2499-506.
3. Kim HJ, Park HJ, Park WS, et al. CD43 cross-linking increases the Fas-induced apoptosis through induction of Fas aggregation in Jurkat T-cells. Exp Mol Med 2006; 38:357-63.
4. Hernandez JD, Nguyen JT, He J, et al. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol 2006; 177:5328-36.
5. He YW, Bevan MJ. High level expression of CD43 inhibits T cell receptor/CD3-mediated apoptosis. J Exp Med 1999; 190:1903-8.
6. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol 1999; 111:488-94.
7. Arber DA, Weiss LM. CD43: a review. Appl Immunohistochem 1993; 1:88-96.
8. de Leon ED, Alkan S, Huang JC, et al. Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. Mod Pathol 1998; 11:1046-51.
9. Hagenbeek A, Gascoyne RD, Dreyling M, et al. Biomarkers and prognosis in malignant lymphomas. Clin Lymphoma Myeloma 2009; 9:160-6.
10. Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007; 21:18-29.
11. Ross CW, Ouillette PD, Saddler CM, et al. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res 2007; 13:4777-85.
12. O'Shea D, O'Riain C, Gupta M, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009; 113:2298-301.
13. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-69.
14. Farinha P, Masoudi H, Skinnider BF, et al. Lymphoma-associated macrophage content is an independent predictor of survival in patients with follicular lymphoma. Blood 2004; 104:890a (Abstract 3259).
15. Kelley T, Beck R, Absi A, et al. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 2007; 48:2403-11.
16. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor infiltrating FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108:2957-64.
17. Alvaro T, Lejeune M, Camacho FI, et al. The presence of STAT1-positive tumorassociated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006; 91:1605-12.
18. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169-74.
19. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25:805-12.
20. de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009; 94:70-7.
21. Wang SS, Maurer MJ, Morton LM, et al. Polymorphisms in DNA repair and onecarbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 2009; 23:596-602.
22. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007; 109:5439-46.
23. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3:185-97.
24. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathological study based on gene expression profiling. Blood 2005; 106:4315-21.
25. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma [published erratum in: Blood 2008; 111:5761]. Blood 2008; 111:558-65.
26. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-11.
27. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-47.
28. Jais JP, Haioun C, Molina TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22:1917-24.
29. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68-74.
30. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275-82.
31. Chen J, Byrne GE Jr, Lossos IS. Optimization of RNA extraction from formalinfixed, paraffin-embedded lymphoid tissues [published erratum in: Diagn Mol Pathol 2007; 16:387]. Diagn Mol Pathol 2007; 16:61-72.
32. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350:1828-37.
33. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111:5509-14.
34. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112:3425-33.
35. National Comprehensive Cancer Network [Web site]. Clinical Recommendations: About the NCCN Clinical Practice Guidelines in Oncology. Available at:
36. Mighell AJ, Hume WJ, Robinson PA. An overview of the complexities and subtleties of immunohistochemistry. Oral Dis 1998; 4:217-23.
37. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53:125-30.
38. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006; 130:1026-30.
39. Bodo J, Durkin L, Hsi ED. Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology. J Histochem Cytochem 2009. E-pub ahead of print.
40. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111:2385-7.
41. Hsi ED, Jung SH, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008; 49:2081-90.
42. National Comprehensive Cancer Network [Web site]. Clinical Recommendations: NCCN Clinical Practice Guidelines in Oncology. Available at: http://www.nccn. org/professionals/physician- gls/f-guidelines.asp